Monthly Archives :

May 2020

THE IMPULSE OF ACCIÓ AND THE CATALONIA REGION TO TRICOPHARMING – STARTUP CAPITAL 2019

150 150 marketing
Startup Capital 2019

 

Glad to announce that Tricopharming has been selected among the 20 most innovative tech startups of Catalonia Region within the framework of the Startup Capital 2019 call!

Startup Capital boosts early stage technological companies helping to accelerate their product development and road map to market by co-financing business plan implementation. 

The call is addressed to high technological Startups located in Catalonia region. The catalan startup ecosystem is very dynamic according to recent regional statistics showing a growing trend in startup number with a total 1.504 in 2019, meaning a 38% more than 3 years ago. In the previous editions of the call, selected StartUp were all standing out for their technological and innovation impact.

Time frame is 18 months, starting in November 2019. The initiative consists in a direct grant of up to 75.000 euros for recently-created technological startups, plus a mentoring program carried out by ACCIO via mentorship specialists and major representatives of the technology, health and biotech industry. The initiative finances measures to implement the business plan and to accelerate access to early stage financing rounds.

Thanks to the project we will be able to conduct on-field beta testing to eventually launch on the market our new business line by the end of 2020. 

On the other side, thanks to Startup Capital financing, we will be able to scale up faster the production and commercialization of our product Artennua®, since 2019 available in the two formats capsules and B2B bags.

That’s a very good news for us! It joins the good results achieved in 2019: at the beginning of 2019 we took part to the Barcelona Activa pre-Acceleration Program – being to date incubated in the MediaTic Tech StartUps @22 district hub, we received the Cervera project co-funding by CDTI for our R&D activity and last but not least, the ‘Seal of Excellence’ by the European Commission in the framework of the SME Instrument phase 1 call.

A BIOCHEMIST FROM CUENCA, IN SEARCH OF A TREATMENT FOR COVID-19

150 150 marketing

Luis Matías, through his company Biotech Tricopharming Research, wants to study the antiviral properties of his product derived from Artemisia annua with the new coronavirus

read more

TRICOPHARMING ON RADIO TELEVISION CANARIA RTVC

150 150 marketing

Artemisia annua plant contains more than 400 metabolites. Among them, stands out the molecule artemisinin, the most effective antimalarial treatment to date. Could Artemisia annua and/or artemisinin molecule be a good candidate to fight Covid-19? This TV news contributes to the debate with our CEO Luís Matías Hernández, PhD, and our Agricultural Engineer Andrés Acosta Pérez by Biotech Tricopharming Research.

Watch the journalistic note of the newscast Telenoticias 1 of Radio Televisión Canaria RTVC.